Gilead Sciences shows positive results for remdesivir as COVID-19 drug
Category: #health  By Mateen Dalal  Date: 2020-05-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Gilead Sciences shows positive results for remdesivir as COVID-19 drug

Gilead Sciences, the maker of remdesivir, has recently revealed positive results from trials for the drug. The trials were conducted to evaluate the potential of the medication as a treatment for the novel coronavirus.

The trials examined the response of patients to either 5-day or 10-day treatments of remdesivir. According to Gilead, the patients undergoing the 5-day treatment showed similar improvement as those treated for twice the timeframe.

Merdad Parsey, Gilead Sciences’ chief medical officer has reportedly stated that the trial shows the potential of certain patients to be treated under the 5-day remdesivir regimen, which could considerably increase the number of patients that could be treated with the present remdesivir supply. This could prove extremely beneficial in the current pandemic setting, enabling healthcare facilities and hospitals to provide efficient treatment to patients in urgent need.

The drug is also being tested locally. For instance, St. Joseph Hospital revealed its plans to conduct some remdesivir trials earlier in the month, which marks a significant feat for the small rural facility. The hospital is conducting two clinical trials, one for moderate symptoms and one to treat more severe symptoms.

Chief executive of St. Joseph Health, Dr. Roberta Luskin-Hawk, stated that one of the patients to receive the treatment was a local patient hospitalized at the St. Joseph Hospital, exhibiting severe COVID-19 symptoms, including dropping oxygen, making them an ideal trial candidate. Dr. Luskin-Hawk also expressed her belief that the drug shows promise as a potential COVID-19 treatment. She also recounted her anticipation to gain access to the drug, in order to leverage its ability to reduce viral loads in patients, especially those suffering from the coronavirus.

The hospital has not offered further information regarding the local trials.

There are no medications currently approved for the treatment of COVID-19, a respiratory disorder that has claimed the lives of over 227,000 people across the globe.

Source Credit: https://www.times-standard.com/2020/04/29/covid-19-drug-shows-promise-in-two-clinical-trials/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...